Results for
"[search-keyword]"
Sponsor content
310 result(s) found, displaying 41 to 50
-
Jan-2024Prescription medicine evaluationActive ingredient: trastuzumab deruxtecan.
-
Jan-2024Prescription medicine evaluationActive ingredient: durvalumab.
-
Jan-2024Prescription medicine evaluationActive ingredient: dapagliflozin propanediol monohydrate.
-
Jan-2024Prescription medicine evaluationActive ingredient: durvalumab.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ANDEXXA andexanet alfa 200 mg powder for injection vial.
-
Australian Public Assessment Report (AusPAR)Imjudo (tremelimumab) is approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian Public Assessment Report (AusPAR)Imfinzi (Durvalumab) has been approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian Public Assessment Report (AusPAR)Andexxa (andexanet alfa) is provisionally approved for adult patients treated with a direct factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IMJUDO tremelimumab 25 mg/ 1.25 mL concentrated injection vial.